Chinese scientists have discovered new results in the study of non-alcoholic fatty liver disease

May 8, the top international magazine
published online the latest research results of a team of Professor Li Hongliang, Dean of the School of Basic Medicine of Wuhan University. The study, entitled "Multibustic regulatory protein Tmbim1 improves non-alcoholic fatty liver disease in mice and monkeys by targeting Thr4 lysosome degradation", reveals for the first time the key negative regulatory role of polybug (MVB) regulatory protein Tmbim1 in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty hepatitis (NASH), and elaborates its molecular mechanism.
this study is another important finding in the field of liver metabolic disease research, which shows that regulating lysosome-mediated protein degradation disorder by targeting MVB regulatory factors is an effective means of treating NASH. The study also provides a new understanding of the pathogenesis of NASH, and provides new targets and strategies for clinical prevention and treatment of NASH and related diseases. Li Hongliang is a co-author of the newsletter, and Dr. Zhao Guangyan, Zhang Peng, Zhang Xiaojing and Doctoral student Gong Jun are co-authors.
reporter learned that NAFLD is China's highest incidence of chronic liver disease type, there are currently more than 150 million patients in China, of which 10% to 20% will be further developed into NASH, manifested in severe inflammatory reactions and liver cell damage, often accompanied by fibrosis. NASH disease progresses rapidly and has a higher risk of developing severe liver diseases such as cirrhosis and hepatocellular carcinoma. At present, there is no effective treatment of NASH clinical drugs worldwide and its pathogenesis is not clear.
it is understood that Li Hongliang's team, which has long been working on cardiovascular and liver metabolic diseases, improved and reversed the NASH process by inhibiting the formation of N-side cojuturation of ASK1, according to a paper published in Nature Medicine in February. The Tmbim1 paper published this time is the same period of CFLAR research.
, according to Li Hongliang, early studies have shown that lysosome-mediated protein degradation disorders are an important part of the NASH process and have become a target for drug development for a variety of diseases. However, it has not been reported whether lysosome-mediated protein degradation can be used as a therapeutic target for NASH.
The project began in 2008, after nearly 9 years of exploration, using a variety of genetically engineered animal disease models and molecular biology means, finally proved that Tmbim1 on liver lipid accumulation, insulin resistance, chronic inflammation and fibrosis and other NASH pathological processes play a key inhibitory role. Further in-depth molecular mechanism studies have clarified that Tmbim1 is a new regulatory molecule in the MVB-lysosome path path, which significantly improves and reverses the NASH process by promoting the degradation of the lysosome of Tlr4.
that the achievement was supported by the National Science Foundation for Distinguished Young People, the National Natural Science Foundation of China, the National Science and Technology Support Program and the National Key Research and Development Program. (Source: Science Network Cui Xueqin)